The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

A disposal drop-off for prescriptions and syringes will take place Saturday, April 26, from 10 a.m. to noon at the Jefferson County Health Department, 715 Green Road, Madison. Proper disposal of ...

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

A research team led by scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) made a major breakthrough with the potential to turn IV drugs into oral ...

That doesn’t seem consistent with firing Food and Drug Administration (FDA) facility inspectors and the staff in the policy division of the FDA Office of Generic Drugs, the office that develops ...

today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), simplifying treatment ...

Kennedy Jr., laid off the 17-person team in charge of the National Survey on Drug Use and Health ... The department’s Administration for Children and Families is weeks behind on the annual ...

1,3 Additionally, CAMZYOS is no longer contraindicated with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors, which were adjusted to drug interactions. This provides physicians with greater ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug ... taking an oral pill instead of using needles and syringes.

Analyst calls orforglipron a potential “Ozempic in a pill." At the highest 36mg dose, patients saw an average weight reduction of 7.9% over 40 weeks. Get prepared for the Fed’s next move ...

The next wave of metabolic medicines in development includes oral GLP-1 drugs that work comparably to currently available injectable medicines, and Eli Lilly is taking the lead with Phase 3 ...